Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE. Hospital trials.
To access the webcast and spectacle the powerpoint presentation, suit log on to:. To participate in the seminar call, dial 866-202-4367 (U.S.) or 617-213-8845 (international), passcode: 31176615. A replay of the convoke will be within reach from 12:00 p.m. Eastern Time on August 18, 2008 (6:00 p.m. Central European Time) through Monday, August 25, 2008.
The replay enumerate is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 36380675 About Micromet, Inc. Micromet, Inc. () is a biopharmaceutical companionship developing novel, proprietary antibodies for the healing of Cancer, irritation and autoimmune diseases.
Four of its antibodies are currently in clinical trials, while the leftovers of the outcome duct is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a aspect 2 clinical experimental for the Care of patients with penetrating lymphoblastic leukemia and in a period 1 clinical plague for the therapy of patients with non-Hodgkin's lymphoma. BiTE antibodies note a supplementary rate of antibodies that impel a patient's own cytotoxic T cells, considered the most high "killer cells" of the understanding invulnerable system, to remove Cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc.
MT110 is the another BiTE antibody in clinical trials, and is being developed by Micromet in a step 1 clinical test for the remedying of patients with lung or Gastrointestinal Cancer. The third clinical mount antibody is adecatumumab, also known as MT201, a benignant monoclonal antibody that targets epithelial apartment adhesion molecule (EpCAM)-expressing crammed tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a look 1b clinical bad evaluating adecatumumab in alliance with docetaxel for the curing of patients with metastatic heart Cancer.
The fourth clinical status antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a configuration 1 clinical Pain for the treatment of patients with Cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the occurrence and commercialization of MT203, a hominoid antibody neutralizing the project of granulocyte/macrophage colony thought-provoking component (GM-CSF), which has embryonic applications in the treatment of various fervid and autoimmune diseases, such as rheumatoid Arthritis, psoriasis, or multiple sclerosis.
Forward-Looking Statements This pass out contains traditional forward-looking statements that imply risks and uncertainties that could cause factual results to be palpably many from true results or from any later results expressed or implied by such forward-looking statements. These forward-looking statements count statements with regard to the efficacy, sanctuary and intended utilization of our artifact candidates, the improvement of our BiTE antibody technology, the conduct, timing and results of tomorrow clinical trials, expectations of the prospective swelling of our spin-off pipe and collaborations, and our plans concerning coming presentations of clinical data. You are urged to take into statements that incorporate the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negating of those words or Other almost identical words to be changeable and forward-looking. Factors that may cause present results to diverge essentially from any subsequent results expressed or implied by any forward-looking statements involve the gamble that merchandise candidates that appeared heartening in ancient research, preclinical studies or clinical trials do not parade cover and/or efficacy in successive clinical trials, the chance that encouraging results from dawn research, preclinical studies or clinical trials may not be confirmed upon further scrutiny of the elaborate results of such research, preclinical bone up or clinical Trial, the jeopardy that additional dope relating to the safety, efficacy or tolerability of our upshot candidates may be discovered upon further investigation of preclinical or clinical headache data, the peril that we or our collaborators will not gain confirmation to buy and sell our effect candidates, the risks associated with trust on outside financing to meet chief requirements, and the risks associated with confidence on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or administer of further incident and commercialization activities relating to our artefact candidates.
These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the budgetary year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as Other filings by the performers with the SEC. Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, utter only as of the phase made. Micromet, Inc. undertakes no liability to publicly update any forward-looking statements, whether as a consequence of experimental information, tomorrow's events or otherwise.
Esteemed opinion site: read
Related posts
Tags: antibody, clinical, forward, looking, micromet, results, statements